BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

KIF6 Genotyping Assay regulatory update

Celera said FDA issued a not approvable letter for a PMA for its KIF6 Genotyping Assay as an aid in determining the risk of coronary heart disease (CHD) and response to statin therapy. According to Celera,...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >